Lumbokinase capsules
Lumbokinase capsules
CAS: 556743-18-1
Molecular Formula: C12H15N3O2S
Lumbokinase capsules - Names and Identifiers
| Name | Lumbokinase capsules |
| Synonyms | Vermis Lumbrokinase Lumbrukinase Lumbrokinaseis LuMbokinase capsules Lumbokinase capsules lumbrokinase capsules |
| CAS | 556743-18-1 |
| EINECS | 211-390-9 |
Lumbokinase capsules - Physico-chemical Properties
| Molecular Formula | C12H15N3O2S |
| Appearance | Powder |
| Storage Condition | -20℃ |
| Physical and Chemical Properties | Lumbrokinase capsules are enteric-coated capsules containing yellowish powder in the capsule shell. |
| Use | Lumbrokinase has dual functions. In addition to directly hydrolyzing fibrinolytic protein, it can also activate plasminogen into plasminogen, thus indirectly hydrolyzing fibrin. |
Lumbokinase capsules - Reference
| Reference Show more | 1. Wu Yali, Ma Yunan, Zhang Qi, Yu Xianglong, du Shouying. Establishment of an in vitro method for evaluating the anticoagulant activity of earthworm [J]. China Modern Applied Pharmacy, 2019,36(20):2527-2530. 2. Yu Lingli, Liu Shunhui, Xu Xiaopeng. Anti-proliferation effect of lumbrokinase on lung cancer cell line A549 and its mechanism [J]. Journal of Guangdong Pharmaceutical Sciences, 2013, 29(001):79-82. 3. [IF = 5.115] Bo Hu et al."Lumbrokinase/paclitaxel nanotube complex: potential therapeutic applications in the blade cancer." Int J Nanomed. 2018; 13: 3625-3640 4. [IF = 8.947] Ying Wang et al."Functionalized polymeric hybrid micells as an efficient nanational agent for gross imaging and microbiology." Acta Biomater. 2021 Mar;122:278 |
Lumbokinase capsules - Trait
Light yellow to brown powder, with fishy smell and hygroscopicity.
Last Update：2023-08-16 21:32:38
Lumbokinase capsules - Source
It is a histone hydrolase extracted and prepared in the artificial breeding of Eisenia Foetida Savigny.
Last Update：2023-08-16 21:32:38
Lumbokinase capsules - Vitality
≥15000u/mg
Last Update：2023-08-16 21:32:38
Lumbokinase capsules - Reference Information
| overview | this product is an enzyme complex extracted and separated from artificially cultured Eisheng worm, and is a yellowish powder. Contains plasminogen and fibrinogen activators, which also have components similar to tissue-type plasminogen activator (t-PA). |
| pharmacological action | this product is a proteolytic enzyme. animal experiments show that this product has the effect of dissolving rabbit arterial thrombosis and rat inferior vena cava thrombosis, which can obviously shorten the dissolution time of euglobulin in rabbits. Clinical experiments show that this product can reduce fibrinogen content, shorten the dissolution time of superior protein, reduce whole blood viscosity and plasma viscosity, and increase t-PA activity. The activity of fibrinolytic enzyme activator inhibitor is reduced, and the fibrin degradation products are increased. after intravenous injection of 125 Ⅱ labeled lumbrokinase, it tends to zero after 18 h, and the residence time in vivo will not exceed 24 h even for large doses. It indicates that long-term application of the drug will not accumulate in the body. |
| drug interaction | has a synergistic effect with drugs that inhibit platelet function to enhance the anticoagulant effect of the latter. |
| indications | is used for the prevention and treatment of thrombotic and embolic diseases, and is also suitable for the treatment of patients with increased fibrinogen and platelet aggregation rate in ischemic cerebrovascular diseases. It can be used for the treatment of transient ischemic attack and early cerebral thrombosis, and can also be used for the prevention of cerebral thrombosis. It can also be used for the treatment of coronary heart disease, myocardial infarction, sudden deafness, retinitis, central venous obstruction, pulmonary infarction, peripheral vascular embolism, etc. |
| dosage and usage | capsule: 200mg per capsule. Oral, 2 capsules each time, 3 times a day, or as prescribed by the doctor. Take before meals. Every 3 to 4 weeks is a course of treatment, which can be taken for 2 to 3 courses, or it can be taken continuously until the symptoms disappear. intravenous drip: once 2500 ~ 5000U, once a day. |
| adverse reactions | very few have mild headache, dizziness, constipation, nausea, lethargy, itching, rash, diarrhea, etc., and have the phenomenon of lowering blood sugar. Non-toxic. |
| precautions | this product is enteric-coated capsule, which should be taken 0.5h before meals. it is forbidden for those who are allergic to this product; it is forbidden for patients with acute hemorrhage and should be used with caution for those with bleeding tendency. the drug safety of pregnant women, lactating women and children is not clear and should be used with caution. this drug is well tolerated, elderly patients can be administered at regular doses. |
| clinical evaluation | 1560 patients with cerebral infarction took lumbrokinase capsules orally for 21 days. during the treatment, no other cerebrovascular dilator drugs, blood rheology drugs and blood circulation drugs and blood stasis drugs were used. the total effective rate was 88.21%, the apparent efficiency was 68.91%, and the dissolution time of fibrinogen and euglobulin was significantly reduced. There are changes in hemorheology, the X2 test was statistically significant. There were no other adverse reactions except rash, skin itching, nausea and so on after taking medicine in individual cases. another report, using random sampling, double-blind method, according to the unified method to observe the clinical efficacy of lumbrokinase in the treatment of ischemic cerebrovascular disease. 303 cases in the treatment group were taken orally with this product, 2 tablets at a time, 3 times a day, half an hour before meals for 21 days, and 150 cases in the control group. The results showed that the effective rate was 93.7% and the apparent efficiency was 73.6%. After treatment, the fibrinogen content, euglobulin dissolution time, whole blood viscosity, plasma viscosity, and platelet aggregation function in the treatment group all changed significantly. |
| preparations and specifications | tablets: 300,000 U. Capsule: 4000U. Lumbrokinase for injection: 5000U. baiao lumbrokinase, enteric-coated capsule, 230 mg,12 capsules/box, 30 capsules/box, Beijing baiao pharmaceutical. Puenfu capsule, 200 mg,12 capsules/box, Qingdao Shuanglong United Pharmaceutical. |
| storage method | seal and store in a cool and dry place. |
| development prospects | current clinical trials show that lumbrokinase has a definite therapeutic effect on common diseases such as coronary heart disease, angina pectoris, cerebral infarction, diabetes, nephrotic syndrome, pulmonary heart disease and deep venous thrombosis of lower limbs, and has little adverse reaction, and patients are easy to tolerate. Although there are still many problems that need to be solved by large-scale and long-term clinical controlled studies, looking forward to the future, the application of lumbrokinase in clinical diseases will have better prospects. |
| uses | indine kinase capsules are suitable for the treatment and prevention of thrombotic and embolic diseases. It has a restorative effect on ischemic cerebrovascular disease, stroke, paralysis of limbs and language disorders. Take two tablets each time, three times a day, half an hour before meals, 3 to 4 weeks as a course of treatment. |
Last Update：2024-04-09 21:50:46
Supplier List
Spot supply
Product Name: Lumbokinase capsules Visit Supplier Webpage Request for quotationCAS: 556743-18-1
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: Lumbokinase capsules Visit Supplier Webpage Request for quotationCAS: 556743-18-1
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History